Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.83 |
| ▸ | MAPT | P10636 | 6/20 | 0.83 |
| ▸ | MEN1 | O00255 | 5/20 | 0.83 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314479 | 0.92 | MEN1 (0.81) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL3316280 | 0.92 | KMT2A (0.71) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL23052565 | 0.91 | MAPT (1.00) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL23052350 | 0.89 | KMT2A (0.85) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL23052352 | 0.89 | KMT2A (0.85) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL23052355 | 0.88 | KMT2A (0.86) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL3315214 | 0.88 | KDM4E (0.66) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL3312505 | 0.87 | KMT2A (0.63) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL3314124 | 0.87 | KMT2A (0.71) | KMT2AALDH1A1MAPTMEN1POLB | |
| SCHEMBL28674208 | 0.86 | MAOA (0.63) | KMT2AALDH1A1MAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021039824-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | 国立大学法人 岡山大学 | 2021-03-04 | — | — | WO | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | KMT2A 2514/4885ALDH1A1 576/4885MAPT 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.